How much funding has DISCO Pharmaceuticals raised?

DISCO Pharmaceuticals has raised $65.0M in total funding, most recently a Seed round.

Who are DISCO Pharmaceuticals's investors?

DISCO Pharmaceuticals's investors include Ackermans & van Haaren, NRW.BANK, Sofinnova Partners, AbbVie Ventures, M Ventures.

When was DISCO Pharmaceuticals founded?

DISCO Pharmaceuticals was founded in 2022.

Where is DISCO Pharmaceuticals headquartered?

DISCO Pharmaceuticals is headquartered in Cologne, Germany.

What industry is DISCO Pharmaceuticals in?

DISCO Pharmaceuticals operates in Biotech, Healthcare.

How many employees does DISCO Pharmaceuticals have?

DISCO Pharmaceuticals has 11-50 employees.

DISCO Pharmaceuticals

Cologne, Germany · Founded 2022 · $65.0M raised

Biotech

Healthcare

Headquarters: Cologne
Employees: 11–50
Founded: 2022
Business Model: B2B

Website: discopharma.de
Total Funding: $65.0M
Last Round: $42.0M SeedDec 2025
Rounds: 2

About

DISCO Pharmaceuticals is a cancer drug discovery company headquartered in Cologne, Germany, with operations in Schlieren, Switzerland. Founded in May 2022 and spun out of ETH Zürich, DISCO has built a pioneering cell surfaceome mapping platform that expands the universe of druggable targets for oncology. The platform uses cell-surface proteomics combined with advanced protein community mapping to identify novel therapeutic targets on the surface of cancer cells — targets that are largely inaccessible to conventional drug discovery approaches. DISCO's initial discovery programs focus on Small Cell Lung Cancer and microsatellite-stable Colorectal Cancer. In January 2026, the company entered a license agreement with Amgen to advance novel cancer surfaceome-targeted therapies, shortly after completing a €36 million seed financing round.

Summary

DISCO Pharmaceuticals is a Biotech company based in Cologne, Germany, founded in 2022. It has raised $65.0M in total across 2 rounds, most recently a $42.0M Seed round in Dec 2025. Investors include Ackermans & van Haaren, NRW.BANK and Sofinnova Partners.